A double blind, sequential, ascending single dose, placebo-controlled safety, tolerability, and pharmacokinetic and pharmacodynamic study of TC-2216 [Targacept] in healthy young male volunteers
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2008
At a glance
- Drugs TC 2216 (Primary)
- Indications Anxiety disorders; Major depressive disorder
- Focus Adverse reactions
- Sponsors Targacept
- 17 Jul 2008 Status changed from recruiting to completed, from clinicaltrials.gov record.
- 09 Nov 2007 Treatment has been well tolerated in all dose groups evaluated to date.
- 09 Nov 2007 Status changed from initiated to recruiting.